"L’ordre doit prévaloir", tranche Biden face à la mobilisation étudiante pour Gaza
- 54
Le président Joe Biden est sorti de son quasi-silence jeudi sur la mobilisation contre l'offensive israélienne dans la bande de ...
Euronews
Welcome to the official Euronews YouTube channel!
Around the clock, our team of 500 journalists of more than 30 different nationalities gathers news with impartial perspective, beyond the headlines content and voices from across Europe and the world. Our YouTube channel has all this and more, bringing you selected and original content from the world's most trusted news source.
Our mission is to empower people to form their own opinion. We trust in people’s intelligence and ability to make up their own mind and seek to provide our audience with the greatest diversity of viewpoints through journalism that is unapologetically impartial. We don’t trade in bias and outrage, we focus on facts, ideas, and solutions. We believe all views matter.
Euronews was born out of a will to create a strong independent European news channel in 1993. As the only international news media with a European perspective, Euronews is where the world turns to hear what Europe has to say.
Check us out on ⬇️
Lastest news
- Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual Meeting
- Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer
- Keymed Biosciences Announces Long-term Efficacy and Safety Data from a Phase III Clinical Trial of Stapokibart for the Treatment of Moderate-to-severe Atopic Dermatitis
- Thrive with GBA | The Bay to Bay Dialogue held to deepen mutual understanding between China and US
- Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial
- Vintage Energy Ltd (VEN.AX) Odin-2 Appraisal Well Successful